{"pub": "afr", "url": "https://afr.com/companies/healthcare-and-fitness/morningstar-cuts-csl-call-to-sell-from-hold-ahead-of-agm-20191014-p530cv", "downloaded_at": "2019-10-16 01:14:37.972848+00:00", "title": "Morningstar cuts CSL call to 'sell' from 'hold' ahead of AGM", "language": "en", "text": "Morningstar, Inc analyst Nicollette Quinn cut her recommendation for CSL to 'sell' from 'hold' on Wednesday ahead of the blood products giant's annual meeting in Sydney.\n\nCSL - which this week celebrated 25 years as a ASX listed company - provided bullish 2020 guidance in August of 7 per cent to 10 per cent net profit growth at constant currency equating to $US2.05 billion to $US2.11 billion.\n\nThe Melbourne-based CSL has experienced some headwinds in its hemophilia unit, and its announced a change to its distribution model in China by going direct to market which will impact 2020.\n\nCSL celebrates 25 years on ASX, CEO & Managing Director, Mr Paul Perreault and CSLs Chairman, Dr Brian McNamee AFR\n\nFormer CEO Dr Brian McNamee will address the AGM later today - in his first as chairman of $112.7 billion biotechnology firm.\n\nCiti analysts led by John Deakin-Bell said in a recent note that CSL\u2019s Seqirus vaccine unit has upside margin possibility as it shifts to higher-priced products over time, and growth will be driven by increased market share.", "description": "CSL is tipped to provide an outlook update at its Sydney AGM today after outlining bullish 2020 guidance in August for 7 per cent to 10 per cent net profit growth.", "authors": [], "top_image": "https://static.ffx.io/images/$zoom_0.5148%2C$multiply_0.7554%2C$ratio_1.777778%2C$width_1059%2C$x_376%2C$y_192/t_crop_custom/e_sharpen:25%2Cq_85%2Cf_auto/ab57e71b76a4b6501aaca7a430b6bca5335f2c44", "published_at": "2019-10-14"}